Fig. 6: Impact of anti-PDGFRβ on tumor growth, angiogenesis, and tumor microenvironment.

a Tumor growth of T241-FGF-2 fibrosarcomas in response to anti-VEGF, anti-PDGFRβ, and anti-VEGF plus anti-PDGFRβ treatments (n = 7/6/6/7; P(Vehicle vs combination therapy) = 0.0013). Time indicates after the start of treatment. b Microvascular density and perivascular coverage of anti-VEGF-, anti-PDGFRβ-, and anti-VEGF plus anti-PDGFRβ-treated T241-FGF-2 fibrosarcomas. Red indicates CD31⁺ microvessels and blue indicates NG2⁺ pericytes. Bar = 50 μm. c Quantification of CD31⁺ microvessel density (n = 7 each; P(Vehicle vs anti-PDGFRβ) = 0.0047; P(Vehicle vs combination) = 0.0007), NG2⁺ pericyte coverage (n = 7 each; P(Vehicle vs anti-PDGFRβ) < 0.0001; P(Vehicle vs combination) = 0.0002), and NG2⁺ pericyte area (n = 7 each; P(Vehicle vs anti-PDGFRβ) < 0.0001; P(Vehicle vs combination therapy) < 0.0001) of various therapy-treated fibrosarcomas. d Micrographs of vascular perfusion of 2000 kDa dextran (blue) and vascular permeability of 70 kDa dextran (blue) co-stained with CD31⁺ microvessels (red). Bar = 50 μm. e Quantification of perfused vasculature (n = 13/14/12/14; P(Vehicle vs combination) < 0.0001) and vascular leakiness (n = 13/13/10/12; P(Vehicle vs anti-VEGF) = 0.0468; P(Vehicle vs anti-PDGFRβ) = 0.0075; P(Vehicle vs combination) = 0.0007) of various therapy-treated fibrosarcomas. f CAXI⁺ signals of tumor hypoxia. Bar = 100 μm. g Quantification of CAXI⁺ hypoxic signals of various therapy-treated fibrosarcomas (n = 10 each; P(Vehicle vs combination) = 0.0147). h Ki67⁺ proliferative cell signals of various therapy-treated fibrosarcomas. Bar = 50 μm. i Quantification of Ki67⁺ signals in various therapy-treated fibrosarcomas (n = 10 each; P(Vehicle vs combination) < 0.0001). j Quantification of Ki67⁺ and CD31⁺ double-positive signals in various therapy-treated fibrosarcomas (n = 10 each; P(Vehicle vs combination therapy) = 0.0008). k Micrographs of caspase-3⁺ apoptotic cells in various therapy-treated fibrosarcomas. Bar = 50 μm. l Quantification of caspase-3⁺ signals in various therapy-treated fibrosarcomas (n = 10 each; P(Vehicle vs combination therapy) = 0.0088). m Quantification of caspase-3⁺-CD31⁺ double-positive signals in various therapy-treated fibrosarcomas (n = 10 each). anti-PRβ = anti-PDGFRβ; n.s. Not significant; two-tailed student t-test. Data presented as mean ± s.e.m. Experiments were repeated twice. Source data are provided as a Source Data file.